Physician profile
Bryan Wong
NPI 1407953755
$9,023.65
in general payments reported to CMS, 2019-2025
22 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $72.83 · 2021: $391 · 2022: $2,078 · 2023: $284 · 2024: $4,770 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,686 · Food and Beverage: $1,850 · Travel and Lodging: $55.24 · Education: $38.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,686.00 |
| Food and Beverage | $1,849.60 |
| Travel and Lodging | $55.24 |
| Education | $38.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,912.64 | 2024 | |
| Akebia Therapeutics INC | $1,721.56 | 2022-2025 | Vafseo, Auryxia |
| Amgen INC. | $681.37 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Astrazeneca Pharmaceuticals LP | $342.30 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $331.04 | 2022-2024 | Tarpeyo |
| Vifor Pharma, INC. | $298.18 | 2019-2021 | |
| Madrigal Pharmaceuticals | $238.81 | 2025 | Rezdiffra |
| Fresenius USA Marketing, INC. | $201.67 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Glaxosmithkline, LLC. | $190.05 | 2022-2023 | Arexvy, Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $166.48 | 2024-2025 | Voyxact |
| Novartis Pharmaceuticals Corporation | $151.64 | 2024-2025 | |
| Amarin Pharma, INC. | $136.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.11 | 2022-2025 | |
| Baxter Healthcare | $135.72 | 2019 | |
| Travere Therapeutics, INC. | $108.46 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $106.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.53 | 2021 | |
| Novo Nordisk INC | $32.27 | 2024 | Ozempic |
| Ardelyx, INC. | $30.72 | 2024 | Ibsrela |
| Mallinckrodt Enterprises LLC | $28.57 | 2019 | |
| Edwards Lifesciences Corporation | $26.65 | 2019 | |
| Horizon Therapeutics Plc | $13.94 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.